Context Therapeutics
CNTX
24 hedge funds and large institutions have $4.59M invested in Context Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
20% more funds holding
Funds holding: 20 → 24 (+4)
3.06% more ownership
Funds ownership: 22.81% → 25.87% (+3.1%)
27% less capital invested
Capital invested by funds: $6.32M → $4.59M (-$1.73M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$235K |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$180K |
| 3 |
Jane Street
New York
|
+$130K |
| 4 |
Two Sigma Investments
New York
|
+$102K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
+$82.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$98K |
| 2 |
AWS
Atria Wealth Solutions
New York
|
-$51K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8K |
CNTX Hedge Fund Activity: Q3 2022 in Review
24 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q3 2022, worth a combined $4.59M — down 27% from $6.32M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CNTX positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $235K. The largest seller was Virtu Financial, exiting entirely with an estimated $98K sold.
- 24 institutional investors held Context Therapeutics (CNTX) as of Q3 2022, up from 20 in Q2 2022.
- Funds reported $4.59M of Context Therapeutics stock for Q3 2022, down 27% quarter-over-quarter.
- 7 funds opened new Context Therapeutics positions in Q3 2022 and 3 closed out, a net change of +4 holders.
- The largest Context Therapeutics buyer in Q3 2022 was Renaissance Technologies, an estimated $235K added.
- The largest Context Therapeutics seller in Q3 2022 was Virtu Financial, an estimated $98K sold.
Based on aggregated 13F filings for Q3 2022.